カテゴリ： 世界, 消費財/食品, QYResearch

MET阻害薬の世界市場2023年：C-Met生物学的阻害剤、低分子C-Met阻害剤、C-Metアンタゴニスト抗体、HGFアンタゴニスト抗体、クリングルバリアントアンタゴニスト

■ 英語タイトル：Global MET Inhibitor Drugs Market Research Report 2023

調査会社QYResearch社が発行したリサーチレポート（データ管理コード：QYR23MA8815）■ 発行会社/調査会社：QYResearch
■ 商品コード：QYR23MA8815
■ 発行日：2023年3月
■ 調査対象地域：グローバル
■ 産業分野：医薬品
■ ページ数：96
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（受注後2-3営業日）
■ 販売価格オプション（消費税別）
Single User（1名様閲覧用）USD2,900 ⇒換算￥440,800見積依頼/購入/質問フォーム
Multi User（5名様閲覧用）USD4,350 ⇒換算￥661,200見積依頼/購入/質問フォーム
Enterprise License（同一法人内共有可）USD5,800 ⇒換算￥881,600見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※QYResearch社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[MET阻害薬の世界市場2023年：C-Met生物学的阻害剤、低分子C-Met阻害剤、C-Metアンタゴニスト抗体、HGFアンタゴニスト抗体、クリングルバリアントアンタゴニスト]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

本調査資料はMET阻害薬のグローバル市場について調査・分析し、世界のMET阻害薬市場概要、メーカー別競争状況、地域別市場規模、タイプ別セグメント分析（C-Met生物学的阻害剤、低分子C-Met阻害剤、C-Metアンタゴニスト抗体、HGFアンタゴニスト抗体、クリングルバリアントアンタゴニスト）、用途別セグメント分析（病院薬局、小売店、その他）、主要企業のプロファイル、市場動向などに関する情報を掲載しています。主要企業としては、Abbott Laboratories、Johnson and Johnson、Novartis International AG、Eli Lilly and Company、Pfizer Inc., Merck & Co.、Takeda Pharmaceutical Company、GlaxosmithKline plc、Amgen Inc.、Bristol Myers Squibb、Daiichi Sankyo Company, Limitedなどが含まれています。MET阻害薬のグローバル市場は、2022年にXXX米ドル、2029年にはXXX米ドルに達すると予測され、予測期間の年平均成長率はXXX％です。新型コロナとロシア・ウクライナ戦争の影響は、MET阻害薬市場規模を算出する際に考慮しました。

・MET阻害薬市場の概要
- 製品の定義
- MET阻害薬の種類別セグメント
- 世界のMET阻害薬市場規模：タイプ別分析（C-Met生物学的阻害剤、低分子C-Met阻害剤、C-Metアンタゴニスト抗体、HGFアンタゴニスト抗体、クリングルバリアントアンタゴニスト）
- MET阻害薬の用途別セグメント
- 世界のMET阻害薬市場規模：用途別分析（病院薬局、小売店、その他）
- 世界のMET阻害薬市場規模予測（2018年-2029年）
- MET阻害薬の平均価格推移（2018年-2029年）
- 前提条件と制限事項

・メーカー別競争状況
- メーカー別市場シェア
- 世界の主要メーカー、業界ランキング分析
- メーカー別平均価格
- MET阻害薬市場の競争状況およびトレンド

・MET阻害薬の地域別市場規模
- 北米のMET阻害薬市場規模（2018年-2029年）
- 米国のMET阻害薬市場規模（2018年-2029年）
- ヨーロッパのMET阻害薬市場規模（2018年-2029年）
- アジア太平洋のMET阻害薬市場規模（2018年-2029年）
- 中国のMET阻害薬市場規模（2018年-2029年）
- 日本のMET阻害薬市場規模（2018年-2029年）
- 韓国のMET阻害薬市場規模（2018年-2029年）
- インドのMET阻害薬市場規模（2018年-2029年）
- オーストラリアのMET阻害薬市場規模（2018年-2029年）
- 中南米のMET阻害薬市場規模（2018年-2029年）
- 中東・アフリカのMET阻害薬市場規模（2018年-2029年）

・種類別セグメント：C-Met生物学的阻害剤、低分子C-Met阻害剤、C-Metアンタゴニスト抗体、HGFアンタゴニスト抗体、クリングルバリアントアンタゴニスト
- 世界のMET阻害薬のタイプ別販売量（2018年-2023年）
- 世界のMET阻害薬のタイプ別売上（2018年-2023年）
- 世界のMET阻害薬のタイプ別価格

・用途別セグメント：病院薬局、小売店、その他
- 世界のMET阻害薬の用途別販売量（2018年-2023年）
- 世界のMET阻害薬の用途別売上（2018年-2023年）
- 世界のMET阻害薬の用途別価格

・主要企業のプロファイル：企業情報、事業概要、売上、製品ポートフォリオ、動向
Abbott Laboratories、Johnson and Johnson、Novartis International AG、Eli Lilly and Company、Pfizer Inc., Merck & Co.、Takeda Pharmaceutical Company、GlaxosmithKline plc、Amgen Inc.、Bristol Myers Squibb、Daiichi Sankyo Company, Limited

・産業チェーンと販売チャネルの分析
- MET阻害薬産業チェーン分析
- MET阻害薬の主要原材料
- MET阻害薬の販売チャネル
- MET阻害薬のディストリビューター
- MET阻害薬の主要顧客

・MET阻害薬市場ダイナミクス
- MET阻害薬の業界動向
- MET阻害薬市場の成長ドライバ、課題、阻害要因

・調査の結論

・調査手法と情報源

Highlights
The global MET Inhibitor Drugs market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Netherlands-Ukraine War were considered while estimating market sizes.
North American market for MET Inhibitor Drugs is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for MET Inhibitor Drugs is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global manufacturers of MET Inhibitor Drugs include Abbott Laboratories, Johnson and Johnson, Novartis International AG, Eli Lilly and Company, Pfizer Inc., Merck & Co., Takeda Pharmaceutical Company, GlaxosmithKline plc, Amgen Inc. and Bristol Myers Squibb, etc. in 2022, the world’s top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for MET Inhibitor Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding MET Inhibitor Drugs.
The MET Inhibitor Drugs market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global MET Inhibitor Drugs market comprehensively. Regional market sizes, concerning products by type, by application and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the MET Inhibitor Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by type, by application and by regions.
By Company
Abbott Laboratories
Johnson and Johnson
Novartis International AG
Eli Lilly and Company
Pfizer Inc., Merck & Co.
Takeda Pharmaceutical Company
GlaxosmithKline plc
Amgen Inc.
Bristol Myers Squibb
Daiichi Sankyo Company, Limited
Segment by Type
C-Met Biological Inhibitors
Small Molecule C-Met Inhibitors
C-Met Antagonist Antibodies
HGF Antagonist Antibodies
Kringle Variant Antagonists
Segment by Application
Hospital Pharmacies
Retail Pharmacies
Others
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of MET Inhibitor Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of MET Inhibitor Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

*** レポート目次（コンテンツ）***

1 MET Inhibitor Drugs Market Overview
1.1 Product Overview and Scope of MET Inhibitor Drugs
1.2 MET Inhibitor Drugs Segment by Type
1.2.1 Global MET Inhibitor Drugs Market Value Comparison by Type (2023-2029)
1.2.2 C-Met Biological Inhibitors
1.2.3 Small Molecule C-Met Inhibitors
1.2.4 C-Met Antagonist Antibodies
1.2.5 HGF Antagonist Antibodies
1.2.6 Kringle Variant Antagonists
1.3 MET Inhibitor Drugs Segment by Application
1.3.1 Global MET Inhibitor Drugs Market Value by Application: (2023-2029)
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Others
1.4 Global MET Inhibitor Drugs Market Size Estimates and Forecasts
1.4.1 Global MET Inhibitor Drugs Revenue 2018-2029
1.4.2 Global MET Inhibitor Drugs Sales 2018-2029
1.4.3 Global MET Inhibitor Drugs Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 MET Inhibitor Drugs Market Competition by Manufacturers
2.1 Global MET Inhibitor Drugs Sales Market Share by Manufacturers (2018-2023)
2.2 Global MET Inhibitor Drugs Revenue Market Share by Manufacturers (2018-2023)
2.3 Global MET Inhibitor Drugs Average Price by Manufacturers (2018-2023)
2.4 Global MET Inhibitor Drugs Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of MET Inhibitor Drugs, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of MET Inhibitor Drugs, Product Type & Application
2.7 MET Inhibitor Drugs Market Competitive Situation and Trends
2.7.1 MET Inhibitor Drugs Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest MET Inhibitor Drugs Players Market Share by Revenue
2.7.3 Global MET Inhibitor Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 MET Inhibitor Drugs Retrospective Market Scenario by Region
3.1 Global MET Inhibitor Drugs Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global MET Inhibitor Drugs Global MET Inhibitor Drugs Sales by Region: 2018-2029
3.2.1 Global MET Inhibitor Drugs Sales by Region: 2018-2023
3.2.2 Global MET Inhibitor Drugs Sales by Region: 2024-2029
3.3 Global MET Inhibitor Drugs Global MET Inhibitor Drugs Revenue by Region: 2018-2029
3.3.1 Global MET Inhibitor Drugs Revenue by Region: 2018-2023
3.3.2 Global MET Inhibitor Drugs Revenue by Region: 2024-2029
3.4 North America MET Inhibitor Drugs Market Facts & Figures by Country
3.4.1 North America MET Inhibitor Drugs Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America MET Inhibitor Drugs Sales by Country (2018-2029)
3.4.3 North America MET Inhibitor Drugs Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe MET Inhibitor Drugs Market Facts & Figures by Country
3.5.1 Europe MET Inhibitor Drugs Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe MET Inhibitor Drugs Sales by Country (2018-2029)
3.5.3 Europe MET Inhibitor Drugs Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific MET Inhibitor Drugs Market Facts & Figures by Country
3.6.1 Asia Pacific MET Inhibitor Drugs Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific MET Inhibitor Drugs Sales by Country (2018-2029)
3.6.3 Asia Pacific MET Inhibitor Drugs Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America MET Inhibitor Drugs Market Facts & Figures by Country
3.7.1 Latin America MET Inhibitor Drugs Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America MET Inhibitor Drugs Sales by Country (2018-2029)
3.7.3 Latin America MET Inhibitor Drugs Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa MET Inhibitor Drugs Market Facts & Figures by Country
3.8.1 Middle East and Africa MET Inhibitor Drugs Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa MET Inhibitor Drugs Sales by Country (2018-2029)
3.8.3 Middle East and Africa MET Inhibitor Drugs Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global MET Inhibitor Drugs Sales by Type (2018-2029)
4.1.1 Global MET Inhibitor Drugs Sales by Type (2018-2023)
4.1.2 Global MET Inhibitor Drugs Sales by Type (2024-2029)
4.1.3 Global MET Inhibitor Drugs Sales Market Share by Type (2018-2029)
4.2 Global MET Inhibitor Drugs Revenue by Type (2018-2029)
4.2.1 Global MET Inhibitor Drugs Revenue by Type (2018-2023)
4.2.2 Global MET Inhibitor Drugs Revenue by Type (2024-2029)
4.2.3 Global MET Inhibitor Drugs Revenue Market Share by Type (2018-2029)
4.3 Global MET Inhibitor Drugs Price by Type (2018-2029)
5 Segment by Application
5.1 Global MET Inhibitor Drugs Sales by Application (2018-2029)
5.1.1 Global MET Inhibitor Drugs Sales by Application (2018-2023)
5.1.2 Global MET Inhibitor Drugs Sales by Application (2024-2029)
5.1.3 Global MET Inhibitor Drugs Sales Market Share by Application (2018-2029)
5.2 Global MET Inhibitor Drugs Revenue by Application (2018-2029)
5.2.1 Global MET Inhibitor Drugs Revenue by Application (2018-2023)
5.2.2 Global MET Inhibitor Drugs Revenue by Application (2024-2029)
5.2.3 Global MET Inhibitor Drugs Revenue Market Share by Application (2018-2029)
5.3 Global MET Inhibitor Drugs Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Abbott Laboratories
6.1.1 Abbott Laboratories Corporation Information
6.1.2 Abbott Laboratories Description and Business Overview
6.1.3 Abbott Laboratories MET Inhibitor Drugs Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Abbott Laboratories MET Inhibitor Drugs Product Portfolio
6.1.5 Abbott Laboratories Recent Developments/Updates
6.2 Johnson and Johnson
6.2.1 Johnson and Johnson Corporation Information
6.2.2 Johnson and Johnson Description and Business Overview
6.2.3 Johnson and Johnson MET Inhibitor Drugs Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Johnson and Johnson MET Inhibitor Drugs Product Portfolio
6.2.5 Johnson and Johnson Recent Developments/Updates
6.3 Novartis International AG
6.3.1 Novartis International AG Corporation Information
6.3.2 Novartis International AG Description and Business Overview
6.3.3 Novartis International AG MET Inhibitor Drugs Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Novartis International AG MET Inhibitor Drugs Product Portfolio
6.3.5 Novartis International AG Recent Developments/Updates
6.4 Eli Lilly and Company
6.4.1 Eli Lilly and Company Corporation Information
6.4.2 Eli Lilly and Company Description and Business Overview
6.4.3 Eli Lilly and Company MET Inhibitor Drugs Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Eli Lilly and Company MET Inhibitor Drugs Product Portfolio
6.4.5 Eli Lilly and Company Recent Developments/Updates
6.5 Pfizer Inc., Merck & Co.
6.5.1 Pfizer Inc., Merck & Co. Corporation Information
6.5.2 Pfizer Inc., Merck & Co. Description and Business Overview
6.5.3 Pfizer Inc., Merck & Co. MET Inhibitor Drugs Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Pfizer Inc., Merck & Co. MET Inhibitor Drugs Product Portfolio
6.5.5 Pfizer Inc., Merck & Co. Recent Developments/Updates
6.6 Takeda Pharmaceutical Company
6.6.1 Takeda Pharmaceutical Company Corporation Information
6.6.2 Takeda Pharmaceutical Company Description and Business Overview
6.6.3 Takeda Pharmaceutical Company MET Inhibitor Drugs Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Takeda Pharmaceutical Company MET Inhibitor Drugs Product Portfolio
6.6.5 Takeda Pharmaceutical Company Recent Developments/Updates
6.7 GlaxosmithKline plc
6.6.1 GlaxosmithKline plc Corporation Information
6.6.2 GlaxosmithKline plc Description and Business Overview
6.6.3 GlaxosmithKline plc MET Inhibitor Drugs Sales, Revenue and Gross Margin (2018-2023)
6.4.4 GlaxosmithKline plc MET Inhibitor Drugs Product Portfolio
6.7.5 GlaxosmithKline plc Recent Developments/Updates
6.8 Amgen Inc.
6.8.1 Amgen Inc. Corporation Information
6.8.2 Amgen Inc. Description and Business Overview
6.8.3 Amgen Inc. MET Inhibitor Drugs Sales, Revenue and Gross Margin (2018-2023)
6.8.4 Amgen Inc. MET Inhibitor Drugs Product Portfolio
6.8.5 Amgen Inc. Recent Developments/Updates
6.9 Bristol Myers Squibb
6.9.1 Bristol Myers Squibb Corporation Information
6.9.2 Bristol Myers Squibb Description and Business Overview
6.9.3 Bristol Myers Squibb MET Inhibitor Drugs Sales, Revenue and Gross Margin (2018-2023)
6.9.4 Bristol Myers Squibb MET Inhibitor Drugs Product Portfolio
6.9.5 Bristol Myers Squibb Recent Developments/Updates
6.10 Daiichi Sankyo Company, Limited
6.10.1 Daiichi Sankyo Company, Limited Corporation Information
6.10.2 Daiichi Sankyo Company, Limited Description and Business Overview
6.10.3 Daiichi Sankyo Company, Limited MET Inhibitor Drugs Sales, Revenue and Gross Margin (2018-2023)
6.10.4 Daiichi Sankyo Company, Limited MET Inhibitor Drugs Product Portfolio
6.10.5 Daiichi Sankyo Company, Limited Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 MET Inhibitor Drugs Industry Chain Analysis
7.2 MET Inhibitor Drugs Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 MET Inhibitor Drugs Production Mode & Process
7.4 MET Inhibitor Drugs Sales and Marketing
7.4.1 MET Inhibitor Drugs Sales Channels
7.4.2 MET Inhibitor Drugs Distributors
7.5 MET Inhibitor Drugs Customers
8 MET Inhibitor Drugs Market Dynamics
8.1 MET Inhibitor Drugs Industry Trends
8.2 MET Inhibitor Drugs Market Drivers
8.3 MET Inhibitor Drugs Market Challenges
8.4 MET Inhibitor Drugs Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

List of Tables
Table 1. Global MET Inhibitor Drugs Market Value Comparison by Type (2023-2029) & (US$ Million)
Table 2. Global MET Inhibitor Drugs Market Value Comparison by Application (2023-2029) & (US$ Million)
Table 3. Global MET Inhibitor Drugs Market Competitive Situation by Manufacturers in 2022
Table 4. Global MET Inhibitor Drugs Sales (K Units) of Key Manufacturers (2018-2023)
Table 5. Global MET Inhibitor Drugs Sales Market Share by Manufacturers (2018-2023)
Table 6. Global MET Inhibitor Drugs Revenue (US$ Million) by Manufacturers (2018-2023)
Table 7. Global MET Inhibitor Drugs Revenue Share by Manufacturers (2018-2023)
Table 8. Global Market MET Inhibitor Drugs Average Price (US$/Unit) of Key Manufacturers (2018-2023)
Table 9. Global Key Players of MET Inhibitor Drugs, Industry Ranking, 2021 VS 2022 VS 2023
Table 10. Global Key Manufacturers of MET Inhibitor Drugs, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of MET Inhibitor Drugs, Product Type & Application
Table 12. Global Key Manufacturers of MET Inhibitor Drugs, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global MET Inhibitor Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in MET Inhibitor Drugs as of 2022)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global MET Inhibitor Drugs Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 17. Global MET Inhibitor Drugs Sales by Region (2018-2023) & (K Units)
Table 18. Global MET Inhibitor Drugs Sales Market Share by Region (2018-2023)
Table 19. Global MET Inhibitor Drugs Sales by Region (2024-2029) & (K Units)
Table 20. Global MET Inhibitor Drugs Sales Market Share by Region (2024-2029)
Table 21. Global MET Inhibitor Drugs Revenue by Region (2018-2023) & (US$ Million)
Table 22. Global MET Inhibitor Drugs Revenue Market Share by Region (2018-2023)
Table 23. Global MET Inhibitor Drugs Revenue by Region (2024-2029) & (US$ Million)
Table 24. Global MET Inhibitor Drugs Revenue Market Share by Region (2024-2029)
Table 25. North America MET Inhibitor Drugs Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 26. North America MET Inhibitor Drugs Sales by Country (2018-2023) & (K Units)
Table 27. North America MET Inhibitor Drugs Sales by Country (2024-2029) & (K Units)
Table 28. North America MET Inhibitor Drugs Revenue by Country (2018-2023) & (US$ Million)
Table 29. North America MET Inhibitor Drugs Revenue by Country (2024-2029) & (US$ Million)
Table 30. Europe MET Inhibitor Drugs Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 31. Europe MET Inhibitor Drugs Sales by Country (2018-2023) & (K Units)
Table 32. Europe MET Inhibitor Drugs Sales by Country (2024-2029) & (K Units)
Table 33. Europe MET Inhibitor Drugs Revenue by Country (2018-2023) & (US$ Million)
Table 34. Europe MET Inhibitor Drugs Revenue by Country (2024-2029) & (US$ Million)
Table 35. Asia Pacific MET Inhibitor Drugs Revenue by Region: 2018 VS 2022 VS 2029 (US$ Million)
Table 36. Asia Pacific MET Inhibitor Drugs Sales by Region (2018-2023) & (K Units)
Table 37. Asia Pacific MET Inhibitor Drugs Sales by Region (2024-2029) & (K Units)
Table 38. Asia Pacific MET Inhibitor Drugs Revenue by Region (2018-2023) & (US$ Million)
Table 39. Asia Pacific MET Inhibitor Drugs Revenue by Region (2024-2029) & (US$ Million)
Table 40. Latin America MET Inhibitor Drugs Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 41. Latin America MET Inhibitor Drugs Sales by Country (2018-2023) & (K Units)
Table 42. Latin America MET Inhibitor Drugs Sales by Country (2024-2029) & (K Units)
Table 43. Latin America MET Inhibitor Drugs Revenue by Country (2018-2023) & (US$ Million)
Table 44. Latin America MET Inhibitor Drugs Revenue by Country (2024-2029) & (US$ Million)
Table 45. Middle East & Africa MET Inhibitor Drugs Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 46. Middle East & Africa MET Inhibitor Drugs Sales by Country (2018-2023) & (K Units)
Table 47. Middle East & Africa MET Inhibitor Drugs Sales by Country (2024-2029) & (K Units)
Table 48. Middle East & Africa MET Inhibitor Drugs Revenue by Country (2018-2023) & (US$ Million)
Table 49. Middle East & Africa MET Inhibitor Drugs Revenue by Country (2024-2029) & (US$ Million)
Table 50. Global MET Inhibitor Drugs Sales (K Units) by Type (2018-2023)
Table 51. Global MET Inhibitor Drugs Sales (K Units) by Type (2024-2029)
Table 52. Global MET Inhibitor Drugs Sales Market Share by Type (2018-2023)
Table 53. Global MET Inhibitor Drugs Sales Market Share by Type (2024-2029)
Table 54. Global MET Inhibitor Drugs Revenue (US$ Million) by Type (2018-2023)
Table 55. Global MET Inhibitor Drugs Revenue (US$ Million) by Type (2024-2029)
Table 56. Global MET Inhibitor Drugs Revenue Market Share by Type (2018-2023)
Table 57. Global MET Inhibitor Drugs Revenue Market Share by Type (2024-2029)
Table 58. Global MET Inhibitor Drugs Price (US$/Unit) by Type (2018-2023)
Table 59. Global MET Inhibitor Drugs Price (US$/Unit) by Type (2024-2029)
Table 60. Global MET Inhibitor Drugs Sales (K Units) by Application (2018-2023)
Table 61. Global MET Inhibitor Drugs Sales (K Units) by Application (2024-2029)
Table 62. Global MET Inhibitor Drugs Sales Market Share by Application (2018-2023)
Table 63. Global MET Inhibitor Drugs Sales Market Share by Application (2024-2029)
Table 64. Global MET Inhibitor Drugs Revenue (US$ Million) by Application (2018-2023)
Table 65. Global MET Inhibitor Drugs Revenue (US$ Million) by Application (2024-2029)
Table 66. Global MET Inhibitor Drugs Revenue Market Share by Application (2018-2023)
Table 67. Global MET Inhibitor Drugs Revenue Market Share by Application (2024-2029)
Table 68. Global MET Inhibitor Drugs Price (US$/Unit) by Application (2018-2023)
Table 69. Global MET Inhibitor Drugs Price (US$/Unit) by Application (2024-2029)
Table 70. Abbott Laboratories Corporation Information
Table 71. Abbott Laboratories Description and Business Overview
Table 72. Abbott Laboratories MET Inhibitor Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 73. Abbott Laboratories MET Inhibitor Drugs Product
Table 74. Abbott Laboratories Recent Developments/Updates
Table 75. Johnson and Johnson Corporation Information
Table 76. Johnson and Johnson Description and Business Overview
Table 77. Johnson and Johnson MET Inhibitor Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 78. Johnson and Johnson MET Inhibitor Drugs Product
Table 79. Johnson and Johnson Recent Developments/Updates
Table 80. Novartis International AG Corporation Information
Table 81. Novartis International AG Description and Business Overview
Table 82. Novartis International AG MET Inhibitor Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 83. Novartis International AG MET Inhibitor Drugs Product
Table 84. Novartis International AG Recent Developments/Updates
Table 85. Eli Lilly and Company Corporation Information
Table 86. Eli Lilly and Company Description and Business Overview
Table 87. Eli Lilly and Company MET Inhibitor Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 88. Eli Lilly and Company MET Inhibitor Drugs Product
Table 89. Eli Lilly and Company Recent Developments/Updates
Table 90. Pfizer Inc., Merck & Co. Corporation Information
Table 91. Pfizer Inc., Merck & Co. Description and Business Overview
Table 92. Pfizer Inc., Merck & Co. MET Inhibitor Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 93. Pfizer Inc., Merck & Co. MET Inhibitor Drugs Product
Table 94. Pfizer Inc., Merck & Co. Recent Developments/Updates
Table 95. Takeda Pharmaceutical Company Corporation Information
Table 96. Takeda Pharmaceutical Company Description and Business Overview
Table 97. Takeda Pharmaceutical Company MET Inhibitor Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 98. Takeda Pharmaceutical Company MET Inhibitor Drugs Product
Table 99. Takeda Pharmaceutical Company Recent Developments/Updates
Table 100. GlaxosmithKline plc Corporation Information
Table 101. GlaxosmithKline plc Description and Business Overview
Table 102. GlaxosmithKline plc MET Inhibitor Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 103. GlaxosmithKline plc MET Inhibitor Drugs Product
Table 104. GlaxosmithKline plc Recent Developments/Updates
Table 105. Amgen Inc. Corporation Information
Table 106. Amgen Inc. Description and Business Overview
Table 107. Amgen Inc. MET Inhibitor Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 108. Amgen Inc. MET Inhibitor Drugs Product
Table 109. Amgen Inc. Recent Developments/Updates
Table 110. Bristol Myers Squibb Corporation Information
Table 111. Bristol Myers Squibb Description and Business Overview
Table 112. Bristol Myers Squibb MET Inhibitor Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 113. Bristol Myers Squibb MET Inhibitor Drugs Product
Table 114. Bristol Myers Squibb Recent Developments/Updates
Table 115. Daiichi Sankyo Company, Limited Corporation Information
Table 116. Daiichi Sankyo Company, Limited Description and Business Overview
Table 117. Daiichi Sankyo Company, Limited MET Inhibitor Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 118. Daiichi Sankyo Company, Limited MET Inhibitor Drugs Product
Table 119. Daiichi Sankyo Company, Limited Recent Developments/Updates
Table 120. Key Raw Materials Lists
Table 121. Raw Materials Key Suppliers Lists
Table 122. MET Inhibitor Drugs Distributors List
Table 123. MET Inhibitor Drugs Customers List
Table 124. MET Inhibitor Drugs Market Trends
Table 125. MET Inhibitor Drugs Market Drivers
Table 126. MET Inhibitor Drugs Market Challenges
Table 127. MET Inhibitor Drugs Market Restraints
Table 128. Research Programs/Design for This Report
Table 129. Key Data Information from Secondary Sources
Table 130. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of MET Inhibitor Drugs
Figure 2. Global MET Inhibitor Drugs Market Value Comparison by Type (2023-2029) & (US$ Million)
Figure 3. Global MET Inhibitor Drugs Market Share by Type in 2022 & 2029
Figure 4. C-Met Biological Inhibitors Product Picture
Figure 5. Small Molecule C-Met Inhibitors Product Picture
Figure 6. C-Met Antagonist Antibodies Product Picture
Figure 7. HGF Antagonist Antibodies Product Picture
Figure 8. Kringle Variant Antagonists Product Picture
Figure 9. Global MET Inhibitor Drugs Market Value Comparison by Application (2023-2029) & (US$ Million)
Figure 10. Global MET Inhibitor Drugs Market Share by Application in 2022 & 2029
Figure 11. Hospital Pharmacies
Figure 12. Retail Pharmacies
Figure 13. Others
Figure 14. Global MET Inhibitor Drugs Revenue, (US$ Million), 2018 VS 2022 VS 2029
Figure 15. Global MET Inhibitor Drugs Market Size (2018-2029) & (US$ Million)
Figure 16. Global MET Inhibitor Drugs Sales (2018-2029) & (K Units)
Figure 17. Global MET Inhibitor Drugs Average Price (US$/Unit) & (2018-2029)
Figure 18. MET Inhibitor Drugs Report Years Considered
Figure 19. MET Inhibitor Drugs Sales Share by Manufacturers in 2022
Figure 20. Global MET Inhibitor Drugs Revenue Share by Manufacturers in 2022
Figure 21. The Global 5 and 10 Largest MET Inhibitor Drugs Players: Market Share by Revenue in 2022
Figure 22. MET Inhibitor Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2018 VS 2022
Figure 23. Global MET Inhibitor Drugs Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Figure 24. North America MET Inhibitor Drugs Sales Market Share by Country (2018-2029)
Figure 25. North America MET Inhibitor Drugs Revenue Market Share by Country (2018-2029)
Figure 26. United States MET Inhibitor Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 27. Canada MET Inhibitor Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 28. Europe MET Inhibitor Drugs Sales Market Share by Country (2018-2029)
Figure 29. Europe MET Inhibitor Drugs Revenue Market Share by Country (2018-2029)
Figure 30. Germany MET Inhibitor Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 31. France MET Inhibitor Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 32. U.K. MET Inhibitor Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 33. Italy MET Inhibitor Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 34. Russia MET Inhibitor Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 35. Asia Pacific MET Inhibitor Drugs Sales Market Share by Region (2018-2029)
Figure 36. Asia Pacific MET Inhibitor Drugs Revenue Market Share by Region (2018-2029)
Figure 37. China MET Inhibitor Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 38. Japan MET Inhibitor Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 39. South Korea MET Inhibitor Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 40. India MET Inhibitor Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 41. Australia MET Inhibitor Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 42. China Taiwan MET Inhibitor Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 43. Indonesia MET Inhibitor Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 44. Thailand MET Inhibitor Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 45. Malaysia MET Inhibitor Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 46. Latin America MET Inhibitor Drugs Sales Market Share by Country (2018-2029)
Figure 47. Latin America MET Inhibitor Drugs Revenue Market Share by Country (2018-2029)
Figure 48. Mexico MET Inhibitor Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 49. Brazil MET Inhibitor Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 50. Argentina MET Inhibitor Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 51. Middle East & Africa MET Inhibitor Drugs Sales Market Share by Country (2018-2029)
Figure 52. Middle East & Africa MET Inhibitor Drugs Revenue Market Share by Country (2018-2029)
Figure 53. Turkey MET Inhibitor Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 54. Saudi Arabia MET Inhibitor Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 55. UAE MET Inhibitor Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 56. Global Sales Market Share of MET Inhibitor Drugs by Type (2018-2029)
Figure 57. Global Revenue Market Share of MET Inhibitor Drugs by Type (2018-2029)
Figure 58. Global MET Inhibitor Drugs Price (US$/Unit) by Type (2018-2029)
Figure 59. Global Sales Market Share of MET Inhibitor Drugs by Application (2018-2029)
Figure 60. Global Revenue Market Share of MET Inhibitor Drugs by Application (2018-2029)
Figure 61. Global MET Inhibitor Drugs Price (US$/Unit) by Application (2018-2029)
Figure 62. MET Inhibitor Drugs Value Chain
Figure 63. MET Inhibitor Drugs Production Process
Figure 64. Channels of Distribution (Direct Vs Distribution)
Figure 65. Distributors Profiles
Figure 66. Bottom-up and Top-down Approaches for This Report
Figure 67. Data Triangulation
Figure 68. Key Executives Interviewed


*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • 麻薬の世界市場2023年：ファストスリープニュー、保定寧混合物、ルミアンバオ、その他複合麻酔薬
  • 婦人科介護医薬品の世界市場2023年：避妊、婦人科感染症、女性感染症、閉経後疾患、婦人科がん、子宮内膜症
  • C1エステラーゼ阻害剤（皮下）の世界市場2023年：500U、1000U
  • 血液腫瘍薬の世界市場2023年：化学療法、標的療法、免疫療法、その他
  • 長時間作用型EPO薬のグローバル市場展望 2023年-2029年：エポエチンアルファ、エポエチンベータ、ダルベポエチンアルファ、その他
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(QYR23MA8815 )"MET阻害薬の世界市場2023年：C-Met生物学的阻害剤、低分子C-Met阻害剤、C-Metアンタゴニスト抗体、HGFアンタゴニスト抗体、クリングルバリアントアンタゴニスト" (英文：Global MET Inhibitor Drugs Market Research Report 2023)はQYResearch社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。